These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27920624)

  • 41. Neoadjuvant therapy for triple negative and HER2-positive early breast cancer.
    Harbeck N; Gluz O
    Breast; 2017 Aug; 34 Suppl 1():S99-S103. PubMed ID: 28666920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Benefit of postoperative regional nodal irradiation in patients receiving preoperative systemic therapy with docetaxel/carboplatin/trastuzumab/pertuzumab for HER2-positive breast cancer.
    Kim N; Kim JY; Park W; Cho WK; Kim TG; Im YH; Ahn JS; Lee JE; Nam SJ; Kim SW; Yu J; Chae BJ; Lee SK; Ryu JM; Park YH; Kim H
    Breast; 2023 Dec; 72():103594. PubMed ID: 37924622
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Optimal Duration of Neoadjuvant Taxane and Carboplatin Combined With Anti-HER2 Targeted Therapy for HER2-Positive Breast Cancer.
    Xie Y; Wu S; Zhang Y; Li J; Mo M; Shao Z; Liu G
    Front Oncol; 2021; 11():686591. PubMed ID: 34168999
    [TBL] [Abstract][Full Text] [Related]  

  • 44. De-escalated neoadjuvant therapy with nanoparticle albumin-bound paclitaxel and trastuzumab for low-risk pure HER2 breast cancer.
    Tanaka S; Matsunami N; Morishima H; Oda N; Takashima T; Noda S; Kashiwagi S; Tauchi Y; Asano Y; Kimura K; Fujioka H; Terasawa R; Kawaguchi K; Ikari A; Morimoto T; Michishita S; Kobayashi T; Sakane J; Nitta T; Sato N; Hokimoto N; Nishida Y; Iwamoto M
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1099-1104. PubMed ID: 30963212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Better predictive value of axillary lymph node (ALN) status after systemic therapy for operable HER2-overexpressing breast cancer: A single-institution retrospective study.
    Zhang Y; Mo M; Li JW; Zhou Y; Wu J; Yu KD; Shen ZZ; Shao ZM; Liu GY
    Eur J Surg Oncol; 2016 Aug; 42(8):1146-52. PubMed ID: 27365197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer.
    Yao L; Zhang J; Liu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Chin J Cancer Res; 2015 Dec; 27(6):553-61. PubMed ID: 26752929
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study.
    van Ramshorst MS; van Werkhoven E; Honkoop AH; Dezentjé VO; Oving IM; Mandjes IA; Kemper I; Smorenburg CH; Stouthard JM; Linn SC; Sonke GS;
    Breast; 2016 Oct; 29():153-9. PubMed ID: 27498129
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Four cycles of adriamycin and cyclophosphamide followed by four cycles of docetaxel (NSABP-B27) with concomitant trastuzumab as neoadjuvant therapy for high-risk, early-stage, HER2-positive breast cancer patients.
    Abdel-Razeq H; Saadeh SS; Abu-Nasser M; Abdulelah H; Marie L; Salam M; Ali BA; Ibrahim M; Rimawi D
    Onco Targets Ther; 2018; 11():2091-2096. PubMed ID: 29695917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
    Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
    JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase II Study of Neoadjuvant Anthracycline-Based Regimens Combined With Nanoparticle Albumin-Bound Paclitaxel and Trastuzumab for Human Epidermal Growth Factor Receptor 2-Positive Operable Breast Cancer.
    Tanaka S; Iwamoto M; Kimura K; Matsunami N; Morishima H; Yoshidome K; Nomura T; Morimoto T; Yamamoto D; Tsubota Y; Kobayashi T; Uchiyama K
    Clin Breast Cancer; 2015 Jun; 15(3):191-6. PubMed ID: 25579459
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
    Fabbri A; Nelli F; Botticelli A; Giannarelli D; Marrucci E; Fiore C; Virtuoso A; Scagnoli S; Pisegna S; Alesini D; Sini V; Orlandi A; Fabi A; Piacentini F; Moscetti L; D'Auria G; Gamucci T; Mazzotta M; Pizzuti L; Vici P; Cretella E; Scavina P; La Cesa A; Persano M; Atzori F; Ruggeri EM
    Front Oncol; 2023; 13():1177681. PubMed ID: 37441419
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.
    Yardley DA; Zubkus JD; Eakle JF; Bechhold RG; Finney L; Daniel D; Daniel B; Hainsworth JD
    Clin Breast Cancer; 2015 Aug; 15(4):251-8. PubMed ID: 25640059
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia.
    Hussain N; Said ASA; Khan Z
    Int J Breast Cancer; 2018; 2018():6106041. PubMed ID: 29850259
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
    Loibl S; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Dan Costa S; Gerber B; Engels K; Nekljudova V; von Minckwitz G; Untch M;
    Ann Oncol; 2017 Mar; 28(3):497-504. PubMed ID: 27831502
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response.
    de Azambuja E; Holmes AP; Piccart-Gebhart M; Holmes E; Di Cosimo S; Swaby RF; Untch M; Jackisch C; Lang I; Smith I; Boyle F; Xu B; Barrios CH; Perez EA; Azim HA; Kim SB; Kuemmel S; Huang CS; Vuylsteke P; Hsieh RK; Gorbunova V; Eniu A; Dreosti L; Tavartkiladze N; Gelber RD; Eidtmann H; Baselga J
    Lancet Oncol; 2014 Sep; 15(10):1137-46. PubMed ID: 25130998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant Efficacy of Three Targeted Therapy Strategies for HER2-Positive Breast Cancer Based on the Same Chemotherapy Regimen.
    Zhu J; Jiao D; Wang C; Lu Z; Chen X; Li L; Sun X; Qin L; Guo X; Zhang C; Qiao J; Yan M; Cui S; Liu Z
    Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139667
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
    Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
    Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study.
    Yang Y; Jin L; Li Y; Rao N; Gong C; Li S; Wu J; Zhao J; Ding L; Gan F; Zhang J; Feng R; Liu Z; Liu Q
    Chin J Cancer Res; 2024 Feb; 36(1):55-65. PubMed ID: 38455369
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant-adjuvant trastuzumab after 2 years of treatment-free follow-up.
    Jackisch C; Hegg R; Stroyakovskiy D; Ahn JS; Melichar B; Chen SC; Kim SB; Lichinitser M; Starosławska E; Kunz G; Falcon S; Chen ST; Crepelle-Fléchais A; Heinzmann D; Shing M; Pivot X
    Eur J Cancer; 2016 Jul; 62():62-75. PubMed ID: 27208905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.